Precise role of H pylori in duodenal ulceration by Hobsley, M et al.
PO Box 2345, Beijing 100023, China                                                                                                                 World J Gastroenterol  2006 October 28; 12(40): 6413-6419
www.wjgnet.com                                                                                                                                          World Journal of Gastroenterology  ISSN 1007-9327
wjg@wjgnet.com                                                                                                                                                                       © 2006 The WJG Press. All rights reserved.
Precise role of H pylori in duodenal ulceration
Michael Hobsley, Frank I Tovey, John Holton
EDITORIAL
Michael Hobsley, Frank I Tovey, Department of Surgery, Royal 
Free and University College Medical School, London, 
United Kingdom
John Holton, Department of Microbiology, Royal Free and 
University College Medical School, London, United Kingdom
Correspondence to: Michael Hobsley, Fieldside, Barnet Lane, 
Totteridge, London N20 8AS, 
United Kingdom. m.hobsley@ucl.ac.uk
Telephone: +44-208-4456507
Received: 2006-07-12               Accepted: 2006-07-22
Abstract
The facts that H pylori infection is commoner in duodenal 
ulcer (DU) patients than in the normal population, and 
that eradication results in most cases being cured, 
have led to the belief that it causes DU. However, early 
cases of DU are less likely than established ones to be 
infected. H pylori-negative cases are usually ascribed 
to specific associated factors such as non-steroidal 
anti-inflammatory drugs (NSAIDs), Crohn’s disease, 
and hypergastrinaemia, but even after excluding 
these, several H pylori-negative cases remain and are 
particularly common in areas of low prevalence of 
H pylori infection. Moreover, this incidence of H pylori 
negative DU is not associated with a fall in overall 
DU prevalence when compared with countries with a 
higher H pylori prevalence. In countries with a high 
H pylori prevalence there are regional differences in 
DU prevalence, but no evidence of an overall higher 
prevalence of DU than in countries with a low H pylori 
prevalence. There is no evidence that virulence factors 
are predictive of clinical outcome. After healing following 
eradication of H pylori infection DU can still recur. 
Medical or surgical measures to reduce acid output can 
lead to long-term healing despite persistence of H pylori 
infection. Up to half of cases of acute DU perforation are 
H pylori negative. These ﬁ  ndings lead to the conclusion 
that H pylori infection does not itself cause DU, but leads 
to resistance to healing, i.e., chronicity. This conclusion 
is shown not to be incompatible with the universally high 
prevalence of DU compared with controls. 
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INTRODUCTION
The award of the Nobel Prize to Warren and Marshall 
for the discovery of H pylori
[1] was rightly acclaimed by 
the medical profession, because the eradication of the 
organism turns a chronic, relapsing disease into one 
that in most (but not all) cases can be readily cured. The 
prevalence of infection with the organism is greater in 
patients with, than in subjects free of, duodenal ulcer; 
the organism is present in most (but not all) cases of the 
disease; and its removal results in most (though not all) 
cases being cured without relapse. The inference usually 
drawn from this combination of events is that H pylori 
actually causes duodenal ulcer.
    In that case, why do most individuals infected with 
the organism not develop the disease? There has been 
considerable work done exploring the concept that the 
presence or absence of virulence factors explains this 
anomaly, but in a recent publication
[2] we explain why we 
do not ﬁ  nd this hypothesis convincing.
    This unsatisfactory situation, the facts that most 
patients with infection do not have a duodenal ulcer, that, 
geographically, duodenal ulcer prevalence is not related to 
the prevalence of H pylori, and many other anomalies, has 
been highlighted in several review articles, such as H pylori: 
the African Enigma
[3]. The enigma is two-fold: ﬁ  rstly, that 
DU prevalence is not higher in countries with a higher 
prevalence of H pylori infection, secondly, that within these 
countries, despite an uniformly high H pylori prevalence, 
regional differences in DU prevalence are found, that as 
described later, are related to diet but not to smoking, 
genetic or other factors.
    Our continuing search for an explanation of the 
anomalies led us to review all the papers that provide 
evidence about the following: (1) Is H pylori infection 
present at the onset of DU? (2) Is there a dose-response 
relationship between H pylori and DU? (3) Does recurrence 
or non-recurrence of DU after successful treatment 
correlate with H pylori-status? (4) Can we deduce anything 
of importance from the prevalence and distribution of H 
pylori-negative DU?
The present paper analyses the evidence of the 
literature on these subjects and we show how the higher 
prevalence of H pylori in DU than in the normal population 
and some of the other anomalies can be explained by a 
self-consistent theory, but only by relinquishing the belief 
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To the best of our knowledge, no paper has been 
published that contradicts statements in this review. We 
shall be obliged to readers for letting us know about any 
exceptions that we have missed.
Is H pylori infection present at the onset of DU?
One is entitled to expect that the cause always precedes 
its effect. The problem with duodenal ulceration is that 
the patient usually presents to the physician some time 
after the symptoms start: it is unlikely that evidence of 
infection has been sought before the symptoms began. It 
occurred to us to examine the H pylori-status of patients 
with duodenal ulcer in relation to the length of history 
before the initial biopsy that established the diagnosis of 
DU. Assuming the organism was the cause of the ulcer, 
we expected the infection to be manifest at least as often 
in the ﬁ  rst six months as it was more than six months after 
symptoms started. We studied 37 patients: to our surprise, 
5 whose history was of less than six months were H pylori-
negative, the remaining 32, all with a length of history 
greater than six months, were H pylori-positive. The odds 
against this happening by chance were (Fisher’s exact test) 
greater than 1000 to 1
[4]. It looked as though the DU was 
causing the infection, rather than the other way about.
    Searching the literature at that time (2001), we could 
ﬁ  nd only one paper that gave ﬁ  gures for infection status, 
distinguished by different lengths of history
[5]. Repeating 
the search in 2005, we were only able to ﬁ  nd one further 
paper with the appropriate data
[6]. Both these papers 
showed a higher infection rate later compared with earlier 
in the ulcer disease.
    There are two reports
[7,8] which suggest that pre-
existing H pylori infection predisposes to DU based on 
seropositivity. The first paper refers to young inductees 
into the Israeli army and the second to an older population 
in Hawaii. In the ﬁ  rst paper it is noteworthy that 7 of the 
29 reported DU cases were H pylori-negative at the time 
of diagnosis. However, seropositivity does not mean that 
infection is present. After eradication, it can take 5-10 
years for seropositive cases to become seronegative. Many 
children serorevert after childhood infection and in adults 
the conversion/reversion rates per annum vary between 
0.5% and 1%. An approach along these lines therefore 
lacks scientiﬁ  c reliability. 
Dose-response relationship?
The smallest dose is zero. Many patients develop a DU 
in the absence of infection with H pylori. This fact is 
usually explained by invoking ‘special’ causes of DU such 
as Zollinger-Ellison syndrome and non-steroidal anti-
inﬂ  ammatory agents (NSAIDs) (see later), but such causes 
are not always apparent.
    Before the H pylori era, excess gastric hydrochloric acid 
was the favoured aetiology of DU. ‘No acid, no ulcer’ 
has been dogma since Schwartz
[9], and there has been no 
contrary evidence. However, acid is ‘statistically’ greater 
than the normal range in only about 15% of (patients 
with) DU, the rest having acid in the normal range
[10], 
albeit with a tendency to be greater than in the normal 
population. 
    In many countries there is no information about the 
actual prevalence of DU in the overall population, and 
available information is based on figures obtained from 
hospital statistics or small population surveys. From 
information that is available, there is no evidence that 
there is a higher overall prevalence of DU in those 
countries where there is a higher prevalence of H pylori 
infection than in other countries. There is evidence from 
India, China and Africa, however, of differences in DU 
prevalence between areas known to have a high prevalence 
of H pylori infection
[3,11-18] these differences being related 
to the staple diets of the regions
[15-25] rather than to 
smoking, genetic or other factors such as duodenal gastric 
metaplasia. There is evidence that different foods contain 
agents that are either ulcerogenic or ulceroprotective
[25-28].
    In developed countries, where H pylori prevalence 
is about 35% overall, DUs are about 70% H pylori-
positive
[6,29-39]; in developing countries, H pylori prevalence 
is about 70% overall, and DUs are H pylori-positive in 
about 90% of patients
[16,29,30,40-51]. Therefore in all countries 
H pylori-positivity is greater in DU than in non-DU. With 
reference to further discussion, it is notable that in areas of 
low H pylori prevalence there is a high prevalence of H pylori-
negative, non-NSAID, ulcers
[4,6,16,29,30,35,39,40,52-64].
    As mentioned above there is no evidence that the 
prevalence of DU is any greater in countries with a high 
prevalence of H pylori than in those with a low prevalence 
(this finding in itself argues against H pylori being the 
prime cause of DU). The prevalence of DU in London 
is about 11%
[10]. Applying this ﬁ  gure to other developed 
countries, from the ﬁ  gures quoted previously in every 100 
of the population, 35 are H pylori-positive and 65 H pylori-
negative. There are 11 patients with DU, of whom perhaps 
only one is H pylori-negative, so only 10 of the 35 H pylori-
positive subjects get DU. The remaining 25 (25/35, 71%) 
do not. A similar argument in the developing countries 
(again assuming an 11% prevalence) yields an estimate 
that only 10 of the 70 H pylori-positive subjects get DU. 
The remaining 60 of the 70 (86%) do not. The belief that 
H pylori is the prime cause of DU demands an explanation 
of why in 71%-86% of individuals it does not produce a 
DU. 
    Weight of infection can be measured by use of the 
breath test, but no-one has suggested that the greater the 
weight of infection, the greater is the risk of developing 
DU. However, there is excellent evidence that the risk 
of developing DU increases with the rate at which the 
subject secretes gastric juice when maximally stimulated 
with intravenous histamine
[10]. The H pylori-lobby suggests 
that we cannot demonstrate a dose-relationship of DU with 
H pylori because only some strains of the organism possess 
virulence factors (of which many have been reported). It 
is beyond the scope of this paper to go into that topic, but 
there is considerable evidence that virulence factors have 
no relationship to clinical outcome
[2].
Does recurrence of DU correspond with H pylori-status?
The answer is, apparently not very well. Ulcers heal with 
effective medical suppression of acid without eradication 
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[65,66],
 and after surgical procedures ulcers remain 
healed despite persistent H pylori infection
[67-76].
    When H pylori was discovered and the ﬁ  rst results came 
in about the effect of its extirpation, it was claimed that 
removing H pylori ‘cured’ the disease and that relapses 
never occurred. As time passed that picture had to be 
modified: there is no doubt that relapses are much less 
frequent and many patients have no further trouble, but 
there is increasing evidence of a significant recurrence 
rate after eradication of H pylori despite lack of recurrence 
of the infection. Excluding subjects taking NSAIDs, 9 
papers, involving 2928 DU patients in whom H pylori 
had been eradicated as proven by multiple tests, reported 
recurrent ulceration in 182 (6.1%) over a period up to 5 
years
[77-85]. One meta-analysis by Laine of 7 trials subjected 
to strict criteria reports a recurrence rate of 20% within 6 
mo
[82]. Interestingly, a recurrence rate of 6.6% (571/8693) 
up to 2 years is given in 12 papers (including 6 meta-
analyses)
[77,85-97] involving 8693 cases of DU, not excluding 
NSAIDs, in whom H pylori had been eradicated. These 
recurrence rates, with and without NSAIDs, are virtually 
identical (P = 0.4883). In other words, recurrence after 
eradication of H pylori cannot be attributed to NSAIDs. 
The use of multiple tests for H pylori reduced the risk that 
we are dealing here with difficulty in demonstrating the 
presence of H pylori after eradication.
What does H pylori-negative DU tell us?
The phenomenon of H pylori-negative DU is an argument 
against a blanket role for H pylori as a “cause preceding 
effect”. As stated above, this prevalence is greater in 
countries with a low, compared with countries with a high 
prevalence of the organism, even after excluding DU-
associated factors such as Crohn’s disease and the taking 
of NSAIDs. There are 20 such reports
[4,6,29,30,35,39,40,52-64] 
from countries with a low prevalence of H pylori infection 
giving a mean of 14.4% (829/5745) of H pylori-negative 
DU and 5 reports
[48,97-100] with a mean of 3.9% (52/1325), 
P < 0.0001) from countries with a high prevalence.
    Three papers
[101-103] suggest that despite the low H pylori 
prevalence in a population with an increased prevalence of 
H pylori-negative DU, there is no decrease in overall DU 
prevalence. If H pylori were the primary cause of DU then 
one would expect a lower prevalence of DU.
    We can offer one supplementary consideration. 
Perforation of duodenal ulceration might reasonably be 
expected to signify an especially large secretion of gastric 
hydrochloric acid. In this context it is interesting that 
perforation does not seem to be associated with H pylori. 
In 4 reports about patients operated on for perforated 
duodenal ulcer H pylori prevalence was significantly less 
than in uncomplicated duodenal ulceration
[104-107] (in 
2
[104,105] they were indistinguishable from normal controls). 
The only dissenting evidence was from a report by 
Matsukara
[108].
INTERPRETATION
How are we to interpret the undoubted relationships 
between DU, H pylori and gastric acid? The present 
majority view is that H pylori causes DU, not that DU 
causes H pylori. The favourable evidence for the former 
inference is the greater proportion of H pylori-positive 
cases in DU compared with non-DU subjects, and the fact 
that clearing the organisms converts the clinical course 
of DU from chronic relapsing to (mostly) stable healing. 
However, the second of these points is not proof of initial 
causation, merely of an interference with healing leading 
to chronicity of the ulceration.
If H pylori is not the initial cause of DU?
If we reject H pylori as the cause of DU, how can we 
explain the greater proportion of H pylori in DU compared 
with non-DU subjects? H pylori can only live within a 
relatively narrow band of pH. Both highly acid and highly 
alkaline conditions kill the organism
[109,110]. For example, 
in pernicious anaemia the patient is usually H pylori-
positive in the early stages (acid production is reduced 
but still abundant) and then becomes H pylori-negative 
in the later stages (when all acid production has ceased 
and the stomach is exposed to alkaline reflux from the 
duodenum)
[111,112]. 
    These facts suggest that some patients who develop 
a DU may well have so much acid that they are H pylori-
negative. When treated with acid suppression for their 
early symptoms, the gastric acidity may fall enough to 
encourage infection with the organism. At this stage 
they are investigated and found to be H pylori-positive. 
Strange as it may at first seem, we are postulating that 
one interpretation of the link between H pylori and DU 
in cases that are initially H pylori-negative is that DU (via 
its treatment) causes the infection. This would explain the 
greater prevalence of H pylori in the subjects with DU as 
an outcome of treatment with acid-suppressing drugs. 
If the likelihood of a first infection increases with the 
presence of virulence factors in the organism - as seems 
reasonable - this explains why the virulence factors are 
more prevalent in the DU than in the non-DU subjects
[2]. 
    In developing countries with a high prevalence of H pylori 
infection, and where people do not have access to acid-
suppressing drugs and only come to hospital with long-
standing chronic conditions, there is another possible 
explanation. With a high H pylori prevalence of 70% it 
follows that 30% of DU patients initially would be H pylori 
negative and 85% of them will not be hypersecretors 
of acid (See ‘Dose Relationship’ above). As a result of 
continued exposure to the high prevalence of H pylori a 
number of these may become infected, resulting in their 
ulceration becoming unremitting and chronic, and causing 
them to seek medical help. The result again would be a 
higher prevalence of H pylori infection in those diagnosed 
with duodenal ulceration. 
    In addition, the known lability of H pylori infection 
could result in some H pylori positive DUs healing as a 
result of spontaneous disappearance of the infection, 
leaving a preponderance of DU cases with persisting 
infection, thus resulting in a higher prevalence of infection 
in the DU population.
    It is possible to calculate the relationship between the 
fraction of established duodenal ulcer patients who are 
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who are H pylori-positive, and the fraction, X, of those 
initially H pylori-negative duodenal ulcer patients who 
become infected so as to produce the observed increase 
in established DU patients. We have performed these 
calculations on data from 18 reports from countries with a 
high prevalence
[16,29,30,36,40-51,113] and 13 reports from countries 
with a low prevalence of H pylori infection
[5,29-39,114]. The 
values of X were 0.6 in the developing countries, 0.58 
in the developed. The congruence between these two 
estimates, while certainly not proof of our hypothesis, at 
least suggests that our hypothesis should not be rejected 
out of hand. Details of the derivation of the formula and 
the statistical interpretations are given in the Appendix.
    There remain two important problems. (1) Most 
patients with DU have gastric secretion within the range 
of normal (though the chance of getting DU does increase 
with the rate of secretion). There must be some other 
factor to explain why some get an ulcer and others do not. 
Our work
[115] demonstrated that this factor was unlikely 
to be H pylori. We favour the idea that the causative agent 
nevertheless involves interference with wound-healing. 
NSAIDs can interfere with the healing of H pylori-
negative ulcer, so they may be responsible for part of the 
problem, but there is almost certainly more to discover; 
(2) We still do not know how H pylori (which can only live 
in gastric, not in true duodenal mucosa), makes the ulcer 
difﬁ  cult to heal. The presence of colonised gastric mucosa 
within the duodenum might be a factor. H pylori infection 
inhibits healing of wounded duodenal epithelium in vitro 
due to vacA
[116]. Another factor might be the effect that 
the organism has of increasing sub-maximally (gastrin-) 
stimulated gastric juice
[117]. While the mechanism is in 
doubt, the relationship is clear and is the fundamental 
reason why the discovery of H pylori is of such enormous 
importance for the treatment of duodenal ulcer.
CONCLUSION
Our present view is that the relationship between duodenal 
ulcer, H pylori and gastric acid secretion is most likely to be:
  Acid excess or 
some other factors
Duodenal ulcer       Treatment 
(acid suppression)
   H pylori infection 
(if not already present)
Failure to heal
←
←
←
←
APPENDIX
Fraction (= X) of H pylori -ve duodenal ulcers becoming 
H pylori + ve, possibly as a result of antacid treatment
         % Hp+ve DU minus % Hp+ve NUD or Controls
 X = –––––––––––––––––––––––————————
             % Hp -ve NUD or Controls
Hypothesis
Whether or not a subject is H pylori-positive (+ve) or H pylori-
negative (-ve) makes no difference to the likelihood that 
s/he will develop a duodenal ulcer (DU).
    The diagnosis of most subjects with a DU is only made 
after the patient has already been treated with agents that 
reduce gastric acid secretion.
    Reduction in gastric secretion is likely to increase the 
chance that a -ve patient becomes +ve.
    When ﬁ  rst diagnosed, most DU patients will include 
some who were +ve before they developed DU and others 
who had been -ve but became positive during their initial 
treatment and before diagnosis.
Calculation
Let 
P = population
U = fraction having DU
F = fraction of population H pylori +ve 
               (so 1-F = fraction negative)
Then 
Conﬁ  rmed DU (say after 6/12)
           = U × P
However, the confirmed DU is made up of two 
moieties, one originally +ve, the other originally negative.
The originally positive DU number
           = F × U × P. 
The originally negative DU number
           = (1-F) × U × P.
Let a fraction X of the originally negative DU be 
infected as a result of acid-suppression. Then after 6/12 
these will number
           = (1 - F) × U × P × X.
Therefore the observed positive DUs can be expressed as
     (F × U × P) + X[(1-F) × U × P].
Therefore, the observed proportion of DUs who are 
positive is given by
    {(F × U × P) + X(1-F) × U × P}/(U × P )
or, dividing by U × P,
     F + X(1-F).
Therefore,  observed  +ve  DU/(total  DU)  =  {F  +  X(1-F)}          
           = F + X - FX
Therefore, X ( 1-F) = [observed DU+ve/total DU] - F 
And X = {[observed DU+ve/total DU] - F}/(1 - F)}
Analysis of the ﬁ  gures quoted
High prevalence countries: Mean Hp+ DUs = 89.395; 
(SD 7.602, SE 1.700). Mean Hp+ NUD = 68.350 (SD 
12.759, SE 2.853. Mean X = 60.565 (SD 26.466, SE 5.918). 
Low prevalence countries: Mean Hp+DU = 70.221; 
(SD 14.319, SE 3.183). Mean Hp + NUD = 33.286; (SD 
16.014, SE 4.280). Mean X = 58.279; (SD 17.773, SE 4.750) 
Difference between high prevalence and low 
prevalence countries: for Hp + DU, P = 0.0002 (highly 
signiﬁ  cant); for X, P = 0.4109 deﬁ  nitely non-signiﬁ  cant. 
This hypothesis suggests that in all countries there 
is much the same chance of originally H pylori-negative 
becoming infected as the ulcer progresses. This fact 
provides circumstantial evidence, though certainly not 
proof, of our hypothesis.
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